Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye

被引:31
作者
Awwad, Sahar [1 ,2 ,3 ]
Day, Richard M. [4 ]
Khaw, Peng T. [1 ,2 ]
Brocchini, Steve [1 ,2 ,3 ]
Fadda, Hala M. [5 ]
机构
[1] NIHR, Biomed Res Ctr, Moorfields Eye Hosp NHS Fdn Trust, London EC1 V9EL, England
[2] UCL Inst Ophthalmol, London EC1 V9EL, England
[3] UCL Sch Pharm, London WC1N 1AX, England
[4] UCL Div Med, London WC1E 6JJ, England
[5] Butler Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Indianapolis, IN 46208 USA
基金
英国医学研究理事会;
关键词
Ocular drug delivery; Pharmacokinetics; In vitro in vivo correlations; Sustained release; PLGA; INTRAVITREAL DRUG-DELIVERY; INDUCED PHASE-SEPARATION; TRIAMCINOLONE ACETONIDE; NONVITRECTOMIZED EYES; MACULAR DEGENERATION; PHARMACOKINETICS; MICROSPHERES; INJECTION; IMPLANT; DISEASE;
D O I
10.1016/j.ijpharm.2017.02.047
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Corticosteroids have long been used to treat intraocular inflammation by intravitreal injection. We describe dexamethasone loaded poly-DL-lactide-co-glycolide (PLGA) microparticles that were fabricated by thermally induced phase separation (TIPS). The dexamethasone loaded microparticles were evaluated using a two-compartment, in vitro aqueous outflow model of the eye (PK-Eye) that estimates drug clearance time from the back of the eye via aqueous outflow by the anterior route. A dexamethasone dose of 0.20 +/- 0.02 mu g in a 50 mu l volume of TIPS microparticles resulted in a clearance t(1/2) of 9.6 +/- 0.3 days using simulated vitreous in the PIC-Eye. Since corticosteroids can also clear through the retina, it is necessary to account for clearance through the back of the eye. Retinal permeability data, published human ocular pharmacokinetics (PK) and the PK-Eye clearance times were then used to establish in vitro in vivo correlations (IVIVCs) for intraocular clearance times of corticosteroid formulations. A t(1/2) of 48 h was estimated for the dexamethasone TIPS microparticles, which is almost 9 times longer than that reported for dexamethasone suspension in humans. The prediction of human clearance times of permeable molecules from the vitreous compartment can be determined by accounting for drug retinal permeation and determining the experimental clearance via the anterior aqueous outflow pathway using the PK-Eye. (C) 2017 Published by Elsevier B.V.
引用
收藏
页码:119 / 127
页数:9
相关论文
共 40 条
[31]   Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes [J].
Loch, Christian ;
Zakelj, Simon ;
Kristl, Albin ;
Nagel, Stefan ;
Guthoff, Rudolf ;
Weitschies, Werner ;
Seidlitz, Anne .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (01) :131-138
[32]   Electrospray synthesis and properties of hierarchically structured PLGA TIPS microspheres for use as controlled release technologies [J].
Malik, Salman A. ;
Ng, Wing H. ;
Bowen, James ;
Tang, Justin ;
Gomez, Alessandro ;
Kenyon, Anthony J. ;
Day, Richard M. .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2016, 467 :220-229
[33]   Review: Practical issues in intravitreal drug delivery [J].
Maurice, D .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2001, 17 (04) :393-401
[34]   Fluid Mechanics of the Eye [J].
Siggers, Jennifer H. ;
Ethier, C. Ross .
ANNUAL REVIEW OF FLUID MECHANICS, VOL 44, 2012, 44 :347-372
[35]  
Soman N, 2003, BIO-MED MATER ENG, V13, P59
[36]   Intravitreal drug delivery in retinal disease: are we out of our depth? [J].
Thakur, Sachin S. ;
Barnett, Nigel L. ;
Donaldson, Mark J. ;
Parekh, Harendra S. .
EXPERT OPINION ON DRUG DELIVERY, 2014, 11 (10) :1575-1590
[37]   Drug delivery to the posterior segment of the eye [J].
Thrimawithana, Thilini Rasika ;
Young, Simon ;
Bunt, Craig Robert ;
Green, Colin ;
Alany, Raid Ghassan .
DRUG DISCOVERY TODAY, 2011, 16 (5-6) :270-277
[38]   Aqueous humor dynamics in the aging human eye [J].
Toris, CB ;
Yablonski, ME ;
Wang, YL ;
Camras, CB .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1999, 127 (04) :407-412
[39]   Development of Sustained-Release Microspheres for the Delivery of SAR 1118, an LFA-1 Antagonist Intended for the Treatment of Vascular Complications of the Eye [J].
Yandrapu, Sarath ;
Kompella, Uday B. .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (02) :236-248
[40]  
Zhang LH, 2009, INT J NANOMED, V4, P175